3.630SEK0.00%Mkt Cap: 92.40M SEKP/E: —Last update: 2026-05-13
Scandinavian ChemoTech AB (publ), a medical technology company, engages in the radiation physics, surgical oncology, and clinical development in Sweden and internationally. It operates in two divisions, Human Care and An…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
P/B56.72
P/S7.33
EV/EBITDA-17.85
EV/Revenue7.21
EPS (TTM)-0.24
EPS (Forward)—
Cash Flow & Leverage
FCF Yield-1.73%
FCF Margin-12.69%
Operating CF-3.75M SEK
CapEx (TTM)437.00K SEK
Net Debt/EBITDA0.29
Net Debt-1.46M SEK
Technical
SMA 503.761 (-3.5%)
SMA 2004.226 (-14.1%)
Beta1.12
S&P 52W Chg24.23%
Avg Vol (30d)14.35K
Avg Vol (10d)16.62K
Technical Indicators
RSI (14)43.0
MACD-0.0147
MACD Signal0.0217
MACD Hist.-0.0365
BB Upper4.116 SEK
BB Middle3.858 SEK
BB Lower3.600 SEK
BB Width13.39%
ATR (14)0.3135 SEK
Vol Ratio (20d)0.45x
52W Range
1.45534% of range7.760
52W High7.760 SEK
52W Low1.455 SEK
Profitability
Gross Margin83.81%
EBITDA Margin-40.39%
Profit Margin-65.58%
Oper. Margin-49.29%
ROE-252.86%
ROA-61.03%
Revenue Growth13.20%
Earnings Growth—
Balance Sheet
Debt/Equity0.00
Current Ratio0.79
Quick Ratio0.46
Book Value/Sh0.0640 SEK
Cash/Share0.0570 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.23.80M
Float13.07M
Insiders42.26%
Institutions3.37%
Analyst Consensus
Rating—
Target (Mean)6.300 SEK
Target Range6.300 SEK – 6.300 SEK
# Analysts1
Company
Market Cap92.40M SEK
Enterprise Value90.94M SEK
Revenue (TTM)12.61M SEK
Gross Profit10.30M SEK
Net Income (TTM)-8.06M SEK
Revenue/Share0.5140 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees1
Last Price3.630 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—